Before going to market with a new drug, medical device or test, it’s crucial to know how payers will treat it post-approval. Understanding postlaunch coverage restrictions and knowing which payers are likely to publish policy in the first six months to two years allows organizations to design effective marketing strategies. But who has a crystal ball to discern the future? How can anyone predict the response to a launch?
You are here: / / New Paths in Predictive Payer Coverage: Insights drawing from historical metrics that optimize pre- and post-commercialization marketing efforts for new therapies